Leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease


Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.foundationmedicine.com

Recent News

May 2, 2018
Foundation Medicine Announces 2018 First Quarter Results and Recent Highlights

April 26, 2018
Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration

April 26, 2018
Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance Personalized Cancer Care in China

Read More News

Associated Team Members

Alexis Borisy
Partner

Neil Exter
Partner

Sarah Larson
Partner/Chief Human Resources Officer